The Gastric Bypass Stent System as a Treatment for Hepatic Fibrosis in Obese Patients in European Region
NCT ID: NCT06561529
Last Updated: 2025-05-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
10 participants
INTERVENTIONAL
2024-06-13
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
RFA RCT for Pancreatic or Bile Duct Cancer
NCT02166190
Efficacy and Safety of a Fully Covered Self-Expandable Metal Stent for Unresectable HCC
NCT05729867
Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi
NCT01041612
Prospective Evaluation of Winged Biliary Stent Patency in Patients With Benign Biliary Obstruction
NCT03115411
Percutaneous Biodegradable Biliary Stents for the Treatment of Benign Biliary Strictures.
NCT05556668
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment group, subjects will be treated with the Gastric Bypass Stent System implanted
In total, 10 subjects will be enrolled from 2 investigational sites located in Latvia. Any subject participating in this clinical investigation will not be replaced once withdrawn or lost to follow-up. This study includes 3 phases; screening period, procedural period, and a follow-up period. Following screening, subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy (Visit 3; Day 0).
Gastric Bypass Stent System
The Gastric Bypass Stent System is intended to be used in weight loss treatment for obesity holds potential as a non-invasive technique for managing hepatic fibrosis. This clinical investigation will be used to evaluate the safety and performance of the investigational device for the intended use.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gastric Bypass Stent System
The Gastric Bypass Stent System is intended to be used in weight loss treatment for obesity holds potential as a non-invasive technique for managing hepatic fibrosis. This clinical investigation will be used to evaluate the safety and performance of the investigational device for the intended use.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. BMI ≥ 30 kg/m².
3. Medical history suggests suspected or confirmed NASH fibrosis. Meeting any of the following criteria indicates NASH liver fibrosis:
* Historical biochemical tests for fibrosis: PRO-C3 \>14 ng/mL or ELF ≥9
* Fibroscan, transient elastography ≥8.5 kPa, controlled attenuation parameter ≥280 dB/m
* Based on existing pathology review, liver biopsy within \<2 years before the expected randomization shows stage 1B, 2, or 3 fibrosis NASH, with no significant weight change \>5% or medications likely affecting NAS or fibrosis stage.
4. Liver biopsy confirming NASH within 6 months before the randomization date, with liver biopsy fibrosis stage 1-3, NAS ≥3, and at least a score of 1 for the following NAS components:
* Steatosis (0-3 points)
* Ballooning (0-2 points)
* Lobular inflammation (0-3 points)
5. Patients who have not achieved effective results after three months of lifestyle modifications and non-invasive treatments (non-diabetic patients have not achieved a weight loss of 5%, diabetic patients have not achieved a weight loss of 3%).
6. Able and willing to provide informed consent for participation in the clinical investigation and comply with all study procedures and assessments.
Subjects who meet any of the following criteria are not eligible for this clinical investigation:
1. Patients with liver cirrhosis
2. Patients with secondary obesity; a medical condition that has caused weight gain such as endocrine disorders and hypothalamic disorders.
3. Chronic, daily use of systemic anti-inflammatory or corticosteroid medications (e.g., ibuprofen, prednisolone) for more than 1 week (not including low-dose aspirin for cardiac prophylaxis or inhaled corticosteroids).
4. Patients with less than one-year continuous treatment before baseline with hypoglycemic drugs with known weight loss effects (e.g., GLP-1 agonists, SGLT-2 inhibitors, DDP-4 inhibitors).
5. Patients diagnosed with type 1 diabetes.
6. Patients with the function of islet β cell basically lost, C-peptide ≤ 1/2 of the normal low limit, or low and flat C-peptide release curve under glucose load.
7. Patients with significant iron deficiency or iron deficiency anemia upon the Investigator's discretion.
8. Patients with coagulation dysfunction and chronic, daily use of systemic anti-inflammatory or anti-coagulation medication in the past month (not including low-dose aspirin).
9. Patients with severe liver and kidney dysfunction, and a serum creatinine concentration ≥ 180 μmol/L.
10. Patients with Class III heart function of New York Heart Association Functional Classification (NYHA) or higher upon the Investigators evaluation.
11. Patients who have undergone Endoscopic Retrograde Cholangiopancreatography (ERCP) or have a history of cholecystitis or liver abscess, as assessed by medical history and abdominal ultrasound.
12. Patients with a duodenal ulcer, gastric ulcer, or previous and existing pancreatitis, as assessed by abdominal ultrasound, gastroscopy (prior to the procedure at Visit 3), and medical history.
13. Patients with gallstones (diameter ≥ 20 mm) with clinical symptoms as assessed by abdominal ultrasound and medical history.
14. Patients with on-going thyroid dysfunction, not stabilized despite appropriate treatment.
15. Patients with hemorrhage or potential hemorrhage in the digestive tract.
16. Patients with gastrointestinal tract anomalies, such as gastrointestinal tract atresia, or other conditions that would result in failed placement in the gastrointestinal tract, as assessed by gastroscopy (prior to the procedure at Visit 3), abdominal digital gastrointestinal radiography, and medical history.
17. Patients with a history of bowel obstruction or related diseases in the past year.
18. Patients with a history of systemic lupus erythematosus or scleroderma.
19. Patients with severe infections that are not controlled.
20. Patients with poor general condition and having endoscopic contraindications (as evaluated by the Investigator).
21. Pregnant women or planning to become pregnant.
22. Patients with an alcohol dependence or substance abuse.
23. Patients with unstable psychiatric disorders.
24. Patients who are enrolled in another investigational study and have not completed the required follow-up period.
25. Patients with an allergy to any of the components of the investigational device.
26. Patients with any other conditions evaluated by the Investigators as unsuitable for participating in the clinical investigation.
27. Patients who are positive for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus as determined by antibodies, deoxy/ribonucleic acid (DNA/RNA), or antigens.
Note: Anti-HCV positive, but HCV-RNA negative HCV patients can be included, based on investigator's judgement, if it's not the primary reason for the fibrosis. Anti-HBc positive, but HBs-Ag negative patients can be included, based on investigator's judgement.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hangzhou Tangji Medical Technology Co., Ltd.
OTHER
MDCECRO LLC
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
REUH, hospital "lnfectology center of Latvia"
Riga, Rīga, Latvia
Digestive Diseases Centre "GASTRO"
Riga, , Latvia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BL-LV01-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.